146
Participants
Start Date
March 4, 2021
Primary Completion Date
April 21, 2025
Study Completion Date
January 31, 2026
Sirolimus
In the double-blinded phase, sirolimus 1.5mg/day plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate continue on sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
Placebo
In the double-blinded phase, placebo plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate are switched to receive sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
Peking Union Medical College Hospital, Beijing
Shenzhen People's Hospital, Shenzhen
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
The Second Affiliated Hospital of Nanchang University, Nanchang
The First Hospital of China Medical University, Shenyang
First Affiliated Hospital of Kunming Medical University, Kunming
Beijing Municipal Science & Technology Commission
OTHER
North China Pharmaceutical Group Corporation
INDUSTRY
Chinese SLE Treatment And Research Group
OTHER